The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Zephyr AI appoints Allen Chao as CEO, acquires Aster Insights

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Allen Chao was named CEO of Zephyr AI, a company focused on utilizing artificial intelligence to accelerate drug development. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Patricio Polanco named chief of surgical oncology and surgeon-in-chief at Atrium Health Levine Cancer

Patricio M. Polanco, a surgical oncologist specializing in hepato-pancreato-biliary malignancies and minimally invasive and robotic liver and pancreas surgery, has joined Atrium Health as division chief of surgical oncology, surgeon-in-chief for Atrium Health Levine Cancer in Charlotte, North Carolina and inaugural Richard L. White Jr. Endowed Professor of Surgery at Wake Forest University School of Medicine. 
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account